Neuroendocrine Tumor

P2, N=140, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

Accumulated or original chromosomal instability may lead to the development of pituitary carcinoma from PitNET, and MEN1 mutations may also play an important role in the pathogenesis of pituitary carcinoma. These findings may lead to strategies for earlier diagnosis and new treatments for this disease.

Isolated Syn positivity in SMARCA4-UT may represent a clinicopathologically relevant phenotype with potential therapeutic implications. Further studies are needed to clarify its diagnostic value and its possible association with treatment response.

This large real-world series confirms that [¹⁸F]AlF-OC PET/CT is a robust and broadly applicable SSTR imaging modality across diverse NEN subtypes, including tumor groups traditionally underrepresented in prospective trials of SSTR tracers. The tracer demonstrates reliable uptake across grades and organ sites, supporting its routine clinical use as a practical, high-throughput alternative to ⁶⁸Ga-labeled SSAs.

P1, N=16, Not yet recruiting, University of Pennsylvania

Given the role of BCOR in transcriptional repression and developmental regulation, this case suggests a potential contribution of BCOR dysfunction to pancreatic neuroendocrine tumorigenesis. Our findings expand the phenotypic and genotypic spectrum of OFCD syndrome and underscore the importance of long-term surveillance and further accumulation of cases to clarify tumor predisposition in this rare disorder.

Radical orchiectomy remains the treatment of choice. This case emphasizes the critical role of histopathology and immunoprofiling in diagnosis and contributes to refining the clinical understanding of this rare entity.

Collectively, these findings identify IL-1β and CXCL12 as potential critical mediators of the inflammatory crosstalk between adipocytes and PanNET cells. Targeting this signalling axis may therefore represent a promising therapeutic strategy for PanNETs.

Aims of the study were to: 1) test the effects of SF3B1 inhibitor pladienolide B in tumoral lactotroph cells expressing wild-type or mutated SF3B1R625H; 2) investigate SF3B1 impact on tumoral cells responsiveness to DRD2 agonist cabergoline...Indeed, SF3B1 inhibitor pladienolide B exerted antitumoral actions in PRL-PitNET cells bearing wild-type or mutated SF3B1. Moreover, both SF3B1R625H overexpression and SF3B1 genetic silencing reduced DRD2 expression and signaling.

It also minimizes non-tumor tissue, enhancing the specificity of the protein extract. For complete details on the use and execution of this protocol, please refer to Vijayakurup et al.1.

We also outline critical priorities for future clinical trial design, including the integration of predictive biomarkers and the development of standardized retreatment protocols. Further prospective, biomarker-driven studies are required not only to refine patient selection but also to establish whether rechallenge strategy may represent a biologically reasonable and clinically meaningful strategy.